Emerging role of miR-345 and its effective delivery as a potential therapeutic candidate in pancreatic cancer and other cancers

Nagabhishek Sirpu Natesh, Brianna M. White, Maia M.C. Bennett, Metin Uz, Rakhee Rathnam Kalari Kandy, Surinder K. Batra, Surya K. Mallapragada, Satyanarayana Rachagani

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with high mortality, poor prognosis, and palliative treatments, due to the rapid upregulation of alternative compensatory pathways and desmoplastic reaction. miRNAs, small non-coding RNAs, have been recently identified as key players regulating cancer pathogenesis. Dysregulated miRNAs are associated with molecular pathways involved in tumor development, metastasis, and chemoresistance in PDAC, as well as other cancers. Targeted treatment strategies that alter miRNA levels in cancers have promising potential as therapeutic interventions. miRNA-345 (miR-345) plays a critical role in tumor suppression and is differentially expressed in various cancers, including pancreatic cancer (PC). The under-lying mechanism(s) and delivery strategies of miR-345 have been investigated by us previously. Here, we summarize the potential therapeutic roles of miR-345 in different cancers, with emphasis on PDAC, for miRNA drug discovery, development, status, and implications. Further, we focus on miRNA nanodelivery system(s), based on different materials and nanoformulations, specifically for the delivery of miR-345.

Original languageEnglish (US)
Article number1987
JournalPharmaceutics
Volume13
Issue number12
DOIs
StatePublished - Dec 2021

Keywords

  • MiR-345
  • MiRNA nanodelivery
  • PDAC

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Emerging role of miR-345 and its effective delivery as a potential therapeutic candidate in pancreatic cancer and other cancers'. Together they form a unique fingerprint.

Cite this